MediPoint: Peripheral Vascular Stents for the Lower Extremity - APAC Analysis and Market Forecasts
NEW YORK, May 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
MediPoint: Peripheral Vascular Stents for the Lower Extremity - APAC Analysis and Market Forecasts
http://www.reportlinker.com/p01190440/MediPoint-Peripheral-Vascular-Stents-for-the-Lower-Extremity---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment
MediPoint: Peripheral Vascular Stents for the Lower Extremity - APAC Analysis and Market Forecasts
Summary
Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease (PAD) in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. Through GlobalData's analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.
The peripheral vascular stent market is a large and dynamic one that allows stent manufacturers to develop different types of vascular stent platforms for different types of arteries in the lower extremity. As drug-eluting and bioabsorbable stents address the unmet needs of the current peripheral vascular stent market, they will represent the future of stents for treating PAD in the lower extremity. As more long-term clinical data become available demonstrating their superior therapeutic benefits, adoption of drug-eluting and bioabsorbable stents by the medical community will increase in the future. As PAD presents enormous global public health and socioeconomic issues, it is pertinent to find effective treatment modalities that ensure long-term quality results for patients. This report looks at the current peripheral vascular stent market for the lower extremity in various regions, and evaluates the adoption and opportunities for this technology in the major markets.
Scope
- An overview of PAD, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized APAC PVS market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for PVS
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the PVS sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists
Reasons to buy
- Understand the trends shaping and driving APAC PVS Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US PVS Market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in APAC PVS market landscape? Identify, understand and capitalize.
Table of Contents
1 Table of Contents 7
1.1 List of Tables 15
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 25
2.2 Related Reports 25
3 Peripheral Artery Disease 26
3.1 Overview 26
3.2 Anatomy and Physiology 27
3.2.1 Peripheral Arteries of the Lower Extremity 27
3.3 Pathophysiology 29
3.4 Clinical Presentation 30
3.4.1 Symptoms of Peripheral Artery Disease 30
3.4.2 Risk Factors 32
3.4.3 Disease Classification 32
3.4.4 Diagnosis 33
3.5 Clinical Outcomes 35
3.5.1 Treatment Paradigm 35
3.5.2 Treatment Guidelines 35
3.5.3 Treatment Modalities 39
3.5.4 Endovascular Management of PAD 53
3.6 Epidemiology 57
3.6.1 Peripheral Artery Disease 57
3.7 Economic Impact 59
3.7.1 APAC 59
4 Competitive Assessment 61
4.1 Overview 61
4.1.1 Peripheral Vascular Stent Market 61
4.2 Products 64
4.2.1 Bare Metal Stents 64
4.2.2 Drug-Eluting Stents 148
4.2.3 Covered Stents 155
4.2.4 Bioabsorbable Stents 166
5 Unmet Needs 169
5.1 Need for Better Clinical Outcomes in Specific Lesions 169
5.1.1 Chronic Total Occlusions 169
5.1.2 Long Lesions 169
5.1.3 Heavily-Calcified and Uncrossable Lesions 170
5.1.4 Bifurcation Lesions 170
5.2 Need to Improve Medical Therapy 171
5.3 Comparative Studies on Exercise Therapy 171
5.4 Addressing Complications of Lower-Extremity Bypass Surgery 172
5.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 172
5.6 Need for Better Revascularization of the Femoropopliteal Artery 173
5.7 Difficulty in Treating the Infrapopliteal Artery 174
5.8 Lack of Clinical Data 174
5.9 Limited Designs of Low-Profile Devices 175
5.10 Addressing Challenges of Peripheral Stenting 176
5.10.1 Risk of Post-Procedural Complications 176
5.10.2 In-Stent Restenosis 176
5.10.3 Stent Fracture 177
5.10.4 Long-Term Vessel Patency 177
5.10.5 Stent Material 178
5.10.6 Stent Deployment and Deliverability 178
5.10.7 Dual Anti-Platelet Therapy 179
5.10.8 Imaging 179
6 Pipeline Products 180
6.1 Overview 180
6.2 Pipeline by Phase of Development 181
6.3 Pipeline Product Profiles – Peripheral Artery Disease 183
6.3.1 Citation Stent 183
6.3.2 MR-Enhanced Stents 184
6.3.3 ArtiStent 185
6.3.4 Hybrid Dynamic Stent 185
6.3.5 Nipro Corporation Peripheral Stent 185
6.3.6 Yukon 186
6.3.7 iCAST 188
6.3.8 Peritoneal-Lined Stents 190
6.3.9 LifeJacket Stent Graft 191
6.3.10 Esprit BVS 191
6.3.11 Magic Explorer Stent 193
6.3.12 Stanza 195
6.3.13 3D Biotek Bioresorbable Stent 197
6.3.14 Archer Stent 198
6.3.15 ART Stent 199
6.3.16 Amaranth Bioabsorbable Scaffold 199
6.3.17 TephaFLEX Absorbable Peripheral Stent 199
6.3.18 Zorion Medical Stent 200
6.3.19 Summary 200
7 Clinical Trial Analysis 201
7.1 Overview 201
7.2 Trials to Watch 202
7.2.1 Abbott Vascular 202
7.2.2 Atrium Medical Corporation 203
7.2.3 Biotronik 204
7.2.4 480 Biomedical 205
7.2.5 Cook Medical 206
7.2.6 Covidien 207
7.2.7 Flexible Stenting Solutions 208
7.2.8 IDEV Technologies 209
7.2.9 Medtronic 210
7.2.10 Terumo Medical Corporation 211
8 Industry Overview 212
8.1 Procedure Trends 212
8.1.1 Factors Contributing to Rise of Peripheral Interventions 212
8.1.2 APAC 213
8.2 Market Access 215
8.2.1 APAC 215
8.3 Reimbursement Trends 221
8.3.1 APAC 221
8.4 Regulatory Issues/Recalls 223
8.4.1 Regulatory Issues 223
8.4.2 Recalls 223
8.5 Mergers and Acquisitions 225
8.5.1 Abbott Laboratories 225
8.5.2 Atrium Medical Corporation 225
8.5.3 Boston Scientific Corporation 226
8.5.4 Cordis Corporation (Johnson & Johnson) 226
8.5.5 Covidien 226
8.5.6 CR Bard 227
8.5.7 Medtronic 227
8.5.8 Nexeon Stent 227
8.5.9 Terumo Corporation 228
9 Current and Future Players 229
9.1 Overview 229
9.2 Trends in Corporate Strategy 230
9.3 Company Profiles 233
9.3.1 Abbott Vascular 233
9.3.2 Amaranth Medical 235
9.3.3 Arterial Remodeling Technologies 237
9.3.4 Atrium Medical Corporation 239
9.3.5 Bard Peripheral Vascular (C.R. Bard) 241
9.3.6 Biotronik 243
9.3.7 Boston Scientific Corporation 245
9.3.8 3D Biotek 247
9.3.9 480 Biomedical 249
9.3.10 Cook Medical 251
9.3.11 Cordis Corporation (Johnson & Johnson) 253
9.3.12 CorInnova 255
9.3.13 Covidien 257
9.3.14 Cytograft Tissue Engineering 259
9.3.15 Flexible Stenting Solutions 261
9.3.16 IDEV Technologies 263
9.3.17 Kyoto Medical Planning 265
9.3.18 Medtronic 268
9.3.19 Nexeon Stent 270
9.3.20 Nipro Corporation 272
9.3.21 NovoStent Corporation 274
9.3.22 OptiMed 276
9.3.23 PeriTec Biosciences 278
9.3.24 Synergy Flow 280
9.3.25 Tepha 282
9.3.26 Terumo Corporation 284
9.3.27 TissueGen 286
9.3.28 Translumina 288
9.3.29 Vascular Concepts 290
9.3.30 Veryan Medical 292
9.3.31 VueKlar Cardiovascular 294
9.3.32 W.L. Gore & Associates 296
9.3.33 Zorion Medical 298
10 Market Drivers, Opportunities and Barriers 300
10.1 Market Drivers 300
10.1.1 Rising Prevalence of Disease 301
10.1.2 Long-Term Vessel Patency 302
10.1.3 Reducing the Risk of Restenosis 303
10.1.4 Low-Profile Stent System 304
10.1.5 Self-Expanding Nitinol Stents 305
10.1.6 Limb Amputation 306
10.1.7 Cost Considerations 306
10.1.8 Availability of Long-Term Data 307
10.1.9 Avoiding Stent-in-Stent Procedures 308
10.1.10 Reducing the Need for Dual Anti-Platelet Therapy 308
10.1.11 Accurate Stent Placement 308
10.1.12 Expected Launch of Vascular Stent Products in the US 309
10.2 Opportunities 310
10.2.1 Peripheral Stent Market 310
10.2.2 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 312
10.2.3 Biodegradable and Bioabsorbable Stents 313
10.2.4 Target High-Risk Patients 314
10.2.5 Launch Vascular Stents in the Japanese Market 314
10.2.6 Emerging Markets 315
10.3 Market Barriers 316
10.3.1 Slow Adoption 316
10.3.2 High Selling Prices 320
10.3.3 Lack of Reimbursement 320
10.3.4 Substitutes 321
11 Country Outlooks and Forecasts 322
11.1 Overview 322
11.2 Japan 324
11.2.1 Overview 324
11.2.2 Market Analysis 324
11.3 China 326
11.3.1 Overview 326
11.3.2 Market Analysis 326
11.4 India 328
11.4.1 Overview 328
11.4.2 Market Analysis 328
12 Appendix 331
12.1 Bibliography 331
12.2 Abbreviations 350
12.3 Report Methodology 353
12.3.1 Overview 353
12.3.2 Coverage 353
12.3.3 Secondary Research 353
12.3.4 Forecasting Methodology 354
12.4 Physicians and Specialists Included in this Study 355
12.5 Physician Survey 356
12.6 About the Authors 357
12.6.1 Analysts 357
12.6.2 Global Head of Healthcare 358
12.7 About MediPoint 358
12.8 About GlobalData 358
12.9 Contact Us 359
12.10 Disclaimer 359
List of Tables
Table 1: Classification Systems for Determining the Severity of PAD Symptoms 30
Table 2: Risk Factors Associated with Peripheral Artery Disease 32
Table 3: Types of Atherosclerotic Lesions 33
Table 4: TASC II Classification of Iliac Artery Lesions 36
Table 5: TASC II Classification of Femoropopliteal Artery Lesions 37
Table 6: TASC II Classification of Infrapopliteal Artery Lesions 38
Table 7: Complications of Peripheral Artery Bypass Surgery 43
Table 8: Drugs Incorporated Into Drug-Eluting Stents 46
Table 9: Types of Lesions Treated Using Atherectomy 49
Table 10: Prevalence of PAD in Population Age ?65 Years in the APAC Markets, millions, 2010-2019 57
Table 11: Direct and Indirect Healthcare Costs 59
Table 12: APAC* Peripheral Vascular Stent Market ($m) for Each Type of Artery in the Lower Extremity, 2012 62
Table 13: Marketed Bare Metal Stent Products 64
Table 14: Absolute Stent Family Product Portfolio 66
Table 15: Absolute Stent SWOT Analysis, 2013 69
Table 16: Astron Stent Product Portfolio 71
Table 17: Astron Stent SWOT Analysis, 2013 72
Table 18: BioMimics 3D Stent Product Portfolio 73
Table 19: BioMimics 3D Stent SWOT Analysis, 2013 74
Table 20: Complete Stent SE Product Portfolio 75
Table 21: Complete SE Stent SWOT Analysis, 2013 78
Table 22: E-Luminexx Stent Product Portfolio 79
Table 23: E-Luminexx Stent SWOT Analysis, 2013 80
Table 24: Epic Stent Product Portfolio 81
Table 25: Epic Stent SWOT Analysis, 2013 83
Table 26: FlexStent Iliac Stent System Product Portfolio 84
Table 27: FlexStent Iliac Stent System SWOT Analysis, 2013 85
Table 28: LifeStent Vascular Stent System Product Portfolio 86
Table 29: LifeStent Vascular Stent System SWOT Analysis, 2013 89
Table 30: Maris Deep Stent Product Portfolio 90
Table 31: Maris Deep Stent SWOT Analysis, 2013 91
Table 32: Maris Plus Stent Product Portfolio 92
Table 33: Maris Plus Stent SWOT Analysis, 2013 93
Table 34: Misago Stent Product Portfolio 94
Table 35: Misago Stent SWOT Analysis, 2013 96
Table 36: NovoStent Samba Stent System Product Portfolio 97
Table 37: NovoStent Samba Stent System SWOT Analysis, 2013 99
Table 38: Protégé Family of Stents Product Portfolio 100
Table 39: Protégé Family of Stents SWOT Analysis, 2013 102
Table 40: Pulsar 18 Stent Product Portfolio 103
Table 41: Pulsar 18 Stent SWOT Analysis, 2013 104
Table 42: SMART Stent Product Portfolio 105
Table 43: SMART Stent SWOT Analysis, 2013 107
Table 44: Sinus Stent Family Product Portfolio 108
Table 45: Sinus Stent Family SWOT Analysis, 2013 110
Table 46: Supera Veritas Stent Product Portfolio 111
Table 47: Supera Veritas Stent SWOT Analysis, 2013 114
Table 48: Wallstent Product Portfolio 115
Table 49: Wallstent SWOT Analysis, 2013 116
Table 50: Xpert Stent Product Portfolio 117
Table 51: Xpert Stent SWOT Analysis, 2013 119
Table 52: Zilver Stent Product Portfolio 120
Table 53: Zilver Stent SWOT Analysis, 2013 123
Table 54: Assurant Cobalt Stent Product Portfolio 124
Table 55: Assurant Cobalt Stent SWOT Analysis, 2013 126
Table 56: Chromis Deep Stent Product Portfolio 127
Table 57: Chromis Deep Stent SWOT Analysis, 2013 129
Table 58: Dynamic Stent Product Portfolio 130
Table 59: Dynamic Stent SWOT Analysis, 2013 131
Table 60: Express LD Product Portfolio 132
Table 61: Express LD SWOT Analysis, 2013 134
Table 62: IntraStent LD Stent Product Portfolio 135
Table 63: IntraStent LD Stent SWOT Analysis, 2013 136
Table 64: Omnilink Elite Stent Product Portfolio 137
Table 65: Omnilink Elite Stent SWOT Analysis, 2013 139
Table 66: ParaMount Mini GPS Product Portfolio 140
Table 67: ParaMount Mini GPS SWOT Analysis, 2013 141
Table 68: ProStar Stent Product Portfolio 142
Table 69: ProStar Stent SWOT Analysis, 2013 143
Table 70: Scuba Stent Product Portfolio 144
Table 71: Scuba Stent SWOT Analysis, 2013 145
Table 72: Visi-Pro Stent Product Portfolio 146
Table 73: Visi-Pro Stent SWOT Analysis, 2013 147
Table 74: Marketed Drug-Eluting Stent Products 148
Table 75: Xience Prime BTK Stent Product Portfolio 148
Table 76: Xience Prime BTK Stent SWOT Analysis, 2013 150
Table 77: Zilver PTX Stent Product Portfolio 151
Table 78: Zilver PTX Stent SWOT Analysis, 2013 154
Table 79: Marketed Covered Stent Products 155
Table 80: Gore Viabahn Stent Product Portfolio 156
Table 81: Gore Viabahn Stent SWOT Analysis, 2013 159
Table 82: Gore Tigris Stent Product Portfolio 160
Table 83: Gore Tigris Stent SWOT Analysis, 2013 162
Table 84: V12 Covered Stents Product Portfolio 163
Table 85: V12 Covered Stents SWOT Analysis, 2013 165
Table 86: Remedy Stent Product Portfolio 166
Table 87: Remedy Stent SWOT Analysis, 2012 168
Table 88: Global Peripheral Vascular Stent Product Pipeline 182
Table 89: Citation Stent SWOT Analysis, 2013 183
Table 90: MR-Enhanced Stents SWOT Analysis, 2013 184
Table 91: Yukon Stent SWOT Analysis, 2013 187
Table 92: iCAST Stent SWOT Analysis, 2013 189
Table 93: Peritoneal-Lined Stents SWOT Analysis, 2013 190
Table 94: Esprit BVS SWOT Analysis, 2013 192
Table 95: Magic Explorer Stent SWOT Analysis, 2013 194
Table 96: Stanza Stent SWOT Analysis, 2013 196
Table 97: 3D Biotek Bioresorbable Stent SWOT Analysis, 2013 197
Table 98: Archer Stent SWOT Analysis, 2013 198
Table 99: Abbott Vascular Company Profile 233
Table 100: Abbott Vascular, Marketed and Pipeline Vascular Stent Products 234
Table 101: Abbott Vascular SWOT Analysis, 2013 234
Table 102: Amaranth Medical Company Profile 235
Table 103: Amaranth Medical, Pipeline Vascular Stent Product 236
Table 104: Amaranth Medical SWOT Analysis, 2013 236
Table 105: Arterial Remodeling Technologies Company Profile 237
Table 106: Arterial Remodeling Technologies, Pipeline Vascular Stent Product 238
Table 107: Arterial Remodeling Technologies SWOT Analysis, 2013 238
Table 108: Atrium Medical Corporation Company Profile 239
Table 109: Atrium Medical Corporation, Marketed and Pipeline Vascular Stent Products 240
Table 110: Atrium Medical Corporation SWOT Analysis, 2013 240
Table 111: Bard Peripheral Vascular (C.R. Bard) Company Profile 241
Table 112: Bard Peripheral Vascular (C.R. Bard), Marketed Vascular Stent Products 242
Table 113: Bard Peripheral Vascular (C.R. Bard) SWOT Analysis, 2013 242
Table 114: Biotronik Company Profile 243
Table 115: Biotronik, Marketed and Pipeline Vascular Stent Products 244
Table 116: Biotronik SWOT Analysis, 2013 244
Table 117: Boston Scientific Corporation Company Profile 245
Table 118: Boston Scientific Corporation, Marketed Vascular Stent Products 246
Table 119: Boston Scientific Corporation SWOT Analysis, 2013 246
Table 120: Company Profile – 3D Biotek 247
Table 121: 3D Biotek, Pipeline Vascular Stent Product 248
Table 122: 3D Biotek SWOT Analysis, 2013 248
Table 123: 480 Biomedical Company Profile 249
Table 124: 480 Biomedical, Pipeline Vascular Stent Product 250
Table 125: 480 Biomedical SWOT Analysis, 2013 250
Table 126: Cook Medical Company Profile 251
Table 127: Cook Medical, Marketed Vascular Stent Products 252
Table 128: Cook Medical SWOT Analysis, 2013 252
Table 129: Cordis Corporation Company Profile 253
Table 130: Cordis Corporation, Marketed Vascular Stent Product 254
Table 131: Cordis Corporation SWOT Analysis, 2013 254
Table 132: CorInnova Company Profile 255
Table 133: CorInnova, Pipeline Vascular Stent Product 255
Table 134: CorInnova SWOT Analysis, 2013 256
Table 135: Covidien Company Profile 257
Table 136: Covidien, Marketed Vascular Stent Products 258
Table 137: Covidien SWOT Analysis, 2013 258
Table 138: Company Profile – Cytograft Tissue Engineering 259
Table 139: Cytograft Tissue Engineering, Pipeline Vascular Stent Product 260
Table 140: Cytograft Tissue Engineering SWOT Analysis, 2013 260
Table 141: Flexible Stenting Solutions Company Profile 261
Table 142: Flexible Stenting Solutions, Marketed Vascular Stent Product 262
Table 143: Flexible Stenting Solutions SWOT Analysis, 2013 262
Table 144: IDEV Technologies Company Profile 263
Table 145: IDEV Technologies, Marketed Vascular Stent Product 264
Table 146: IDEV Technologies SWOT Analysis, 2013 264
Table 147: Kyoto Medical Planning Company Profile 265
Table 148: Kyoto Medical Planning, Marketed Vascular Stent Product 267
Table 149: Kyoto Medical Planning SWOT Analysis, 2013 267
Table 150: Medtronic Company Profile 268
Table 151: Medtronic's Marketed Vascular Stent Products 269
Table 152: Medtronic SWOT Analysis, 2013 269
Table 153: Nexeon Stent Company Profile 270
Table 154: Nexeon Stent, Pipeline Vascular Stent Product 271
Table 155: Nexeon Stent SWOT Analysis, 2013 271
Table 156: Nipro Corporation Company Profile 272
Table 157: Nipro Corporation, Pipeline Vascular Stent Product 272
Table 158: Nipro Corporation SWOT Analysis, 2013 273
Table 159: NovoStent Corporation Company Profile 274
Table 160: NovoStent Corporation, Marketed Vascular Stent Product 275
Table 161: NovoStent Corporation SWOT Analysis, 2013 275
Table 162: OptiMed Company Profile 276
Table 163: OptiMed, Marketed Vascular Stent Products 277
Table 164: OptiMed SWOT Analysis, 2013 277
Table 165: Company Profile – PeriTec Biosciences 278
Table 166: PeriTec Biosciences, Pipeline Vascular Stent Product 279
Table 167: PeriTec Biosciences SWOT Analysis, 2013 279
Table 168: Synergy Flow Company Profile 280
Table 169: Synergy Flow, Pipeline Vascular Stent Product 280
Table 170: Synergy Flow SWOT Analysis, 2013 281
Table 171: Tepha Company Profile 282
Table 172: Tepha Medical Device, Pipeline Vascular Stent Product 283
Table 173: Tepha SWOT Analysis, 2013 283
Table 174: Terumo Corporation Company Profile 284
Table 175: Terumo Corporation, Marketed Vascular Stent Products 285
Table 176: Terumo Corporation SWOT Analysis, 2013 285
Table 177: TissueGen Company Profile 286
Table 178: TissueGen, Pipeline Vascular Stent Product 286
Table 179: TissueGen SWOT Analysis, 2013 287
Table 180: Translumina Company Profile 288
Table 181: Translumina, Pipeline Vascular Stent Product 289
Table 182: Translumina SWOT Analysis, 2013 289
Table 183: Vascular Concepts Company Profile 290
Table 184: Vascular Concepts, Marketed Vascular Stent Product 290
Table 185: Vascular Concepts SWOT Analysis, 2013 291
Table 186: Company Profile – Veryan Medical 292
Table 187: Veryan Medical, Marketed Vascular Stent Product 293
Table 188: Veryan Medical SWOT Analysis, 2013 293
Table 189: VueKlar Cardiovascular Company Profile 294
Table 190: VueKlar Cardiovascular, Pipeline Vascular Stent Product 295
Table 191: VueKlar Cardiovascular SWOT Analysis, 2013 295
Table 192: W.L. Gore & Associates Company Profile 296
Table 193: W.L. Gore & Associates, Marketed Vascular Stent Products 297
Table 194: W.L. Gore & Associates SWOT Analysis, 2013 297
Table 195: Zorion Medical Company Profile 298
Table 196: Zorion Medical, Pipeline Vascular Stent Product 298
Table 197: Zorion Medical SWOT Analysis, 2013 299
Table 198: Peripheral Vascular Stent Sales ($m) Forecast for Japan, 2010–2019 324
Table 199: Peripheral Vascular Stent Sales ($m) Forecast for China, 2010–2019 326
Table 200: Peripheral Vascular Stent Sales ($m) Forecast for India, 2010–2019 328
Table 201: Physicians Surveyed, By Country 356
List of Figures
Figure 1: Peripheral Arteries of the Lower Extremity 27
Figure 2: Pathophysiology of Peripheral Artery Disease 29
Figure 3: Treatment Modalities – Peripheral Artery Disease 39
Figure 4: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only, APAC, 2012 (n=15) 40
Figure 5: Treatment of PAD, APAC*, 2012 and 2018 (n=15) 42
Figure 6: Types of Stents Used to Treat Peripheral Artery Disease 45
Figure 7: Bare Metal Stent For Treating Peripheral Artery Disease 45
Figure 8: Drug-Eluting Stent for Treating Peripheral Artery Disease 46
Figure 9: Covered Stents For Treating Peripheral Artery Disease 47
Figure 10: Types of Atherectomy 50
Figure 11: Prevalence of PAD in Population Age ?65 Years in the APAC Markets, millions, 2010–2019 58
Figure 12: Global Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity ($), 2012 61
Figure 13: APAC* Peripheral Vascular Stent Market ($m) for Each Type of Artery, 2012 63
Figure 14: Remedy Stent for Treating Peripheral Artery Disease 167
Figure 15: Pipeline Peripheral Vascular Stent Products, 2013 180
Figure 16: Peripheral Vascular Stent Pipeline by Stage of Clinical Development, 2013 181
Figure 17: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, APAC*, 2010–2019 213
Figure 18: Population (? 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, APAC*, 2010–2019 214
Figure 19: Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012 229
Figure 20: Peripheral Vascular Stent Market for Each Type of Artery, Company Share (%), 2012 231
Figure 21: Kyoto Medical Planning, Sales Volume ($m), May 2002–May 2012 266
Figure 22: Likelihood of Physician Adoption of Each Type of Vascular Stent in the Future for Treating Peripheral Artery Disease in the Lower Extremity, Global (n=50) 310
Figure 23: Importance of Each Attribute in Adopting Vascular Stents to Treat Peripheral Artery Disease in the Lower Extremity, Global, (n=50) 311
Figure 24: APAC* Peripheral Vascular Stent Market ($m), 2010-2019 322
Figure 25: APAC* Peripheral Vascular Stents Revenue ($bn), 2012 and 2019 323
Figure 26: Japanese Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 325
Figure 27: Chinese Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 327
Figure 28: Indian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 329
Companies Mentioned
Abbott Vascular
Amaranth Medical
Arterial Remodeling Technologies
Atrium Medical Corporation
Bard Peripheral Vascular (C.R. Bard)
Biotronik
Boston Scientific Corporation
3D Biotek
480 Biomedical
Cook Medical
Cordis Corporation (Johnson & Johnson
To order this report:
Surgical_Equipment Industry: MediPoint: Peripheral Vascular Stents for the Lower Extremity - APAC Analysis and Market Forecasts
__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article